1.18

6.35% -0.08

After Hours: 1.14 -0.04 -3.39%

Lixte Biotechnology Holdings Inc (LIXT)

Overview News Price History Financials Discussions Forecast Stock Split

Lixte Biotechnology Holdings Inc stock is traded at $1.18, with a volume of 8,990. It is down -6.35% in the last 24 hours and down -2.94% over the past month. Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Previous Close:

$1.26

Open:

$1.29

24h Volume:

8,990

Relative Volume:

0.17

Market Cap:

$3.45M

Revenue:

Net Income/Loss:

$-4.69M

P/E Ratio:

-0.5064

EPS:

-2.33

Net Cash Flow:

$-3.81M

1W Performance:

-8.24%

1M Performance:

-2.94%

6M Performance:

-34.81%

1Y Performance:

-60.14%

1-Day Range:

$1.15

$1.3123

1-Week Range:

$1.14

$1.3183

52-Week Range:

$1.02

$3.50

Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile

Name

Lixte Biotechnology Holdings Inc

Sector

Healthcare (1153)

Industry

Biotechnology (664)

Phone

310 203 2902

Address

248 ROUTE 25A, EAST SETAUKET

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

LIXT's Discussions on Twitter

Compare LIXT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LIXT Lixte Biotechnology Holdings Inc	1.18	3.45M	0	-4.69M	-3.81M	-2.33
VRTX Vertex Pharmaceuticals Inc	450.03	129.44B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	558.52	61.42B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	615.11	38.44B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	269.81	33.29B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	241.75	26.95B	3.81B	-644.79M	-669.77M	-6.24

Lixte Biotechnology Holdings Inc Stock (LIXT) Latest News

Apr 19, 2025

Lixte Biotechnology granted extension to meet Nasdaq listing rules By Investing.com - Investing.com India

Apr 19, 2025

Apr 18, 2025

Lixte Biotechnology granted extension to meet Nasdaq listing rules - Investing.com

Apr 18, 2025

Apr 16, 2025

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Down 44.0% in March - Defense World

Apr 16, 2025

Apr 11, 2025

SEC Form 424B4 filed by Lixte Biotechnology Holdings Inc. - Quantisnow

Apr 11, 2025

Mar 31, 2025

LIXTE Launches New Study to Determine if Certain - GlobeNewswire

Mar 31, 2025

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100 - GlobeNewswire

Mar 31, 2025

Major Breakthrough? LIXTE's Cancer Prevention Drug Could Eliminate Pre-Cancerous Cells in Aging Adults - Stock Titan

Mar 31, 2025

Mar 27, 2025

LIXTE Biotechnology Updates Progress On LB-100 In Ovarian And Colorectal Cancer Trials - Nasdaq

Mar 27, 2025

LIXTE Biotechnology Provides Update On Progress with - GlobeNewswire

Mar 27, 2025

Major Breakthrough: LIXTE's Cancer Drug Shows Promise in New GSK, Roche Clinical Trials - Stock Titan

Mar 27, 2025

Mar 24, 2025